Lloyd Aiello
Ophthalmology · Boston, MANPI 1588622104
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $81,586 of the $89,570 with a category attached, or 91.1%. Novo Nordisk AS accounts for 71.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $65,313 and has fallen 71.0% since, to $18,957 in 2023. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $2714.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$64K
- Novo Nordisk$19K
- Optos, Inc.$3K
- Genentech, Inc.$2K
- Samsung Bioepis Co., Ltd.$1K
- Optos PLC$145
Across 31 payments — averaging $99,858 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson$2.1M
- Janssen Research & Development, LLC$878K
- Novo Nordisk AS$46K
- Sanofi US Services Inc.$45K
What the payments were for
- Consulting fees$81,58691%
- Speaking & faculty fees$2,8853%
- Travel & lodging$3,8354%
- Food & beverage$1,2641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 15 | $64,361 |
| Novo Nordisk | 11 | $19,154 |
| Optos, Inc. | 1 | $2,800 |
| Genentech, Inc. | 1 | $1,960 |
| Samsung Bioepis Co., Ltd. | 2 | $1,150 |
| Optos PLC | 3 | $145 |
How this compares
$89,570 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Timolol Maleate | 29 | $1,325 |
| Latanoprost | 35 | $416 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.